The deal between pharma majors Ranbaxy and Teva, for the sale of generic version of the blockbuster cholesterol drug – Lipitor left many in the industry surprised. Vikas Dandekar, Bureau Chief, PharmAsia News tells CNBC-TV18 that the contours of the deal revolved around three scenarios at best.
first published: Dec 14, 2011 09:05 pm
A collection of the most-viewed Moneycontrol videos.
You are already a Moneycontrol Pro user.